{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:36:04Z","timestamp":1790699764678,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020052","name":"National Centre for Cell Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115161","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:24:48Z","timestamp":1781994288000},"page":"115161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-6254","authenticated-orcid":false,"given":"Kalyani","family":"Puranik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7442","authenticated-orcid":false,"given":"Nisharani","family":"Ranpise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-6648","authenticated-orcid":false,"given":"Shubham","family":"Khot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeya","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115161_b0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejpb.2026.115161_b0010","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1039\/D4PM00174E","article-title":"Nose to brain targeting of the donepezil nanostructured lipid carrier in situ gel: formulation, in vitro , ex vivo , in vivo pharmacokinetic and pharmacodynamic characterization","volume":"1","author":"Sonawane","year":"2024","journal-title":"RSC Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.neuropsychologia.2007.10.026","article-title":"Mapping progressive brain structural changes in early Alzheimer\u2019s disease and mild cognitive impairment","volume":"46","author":"Apostolova","year":"2008","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.ejpb.2026.115161_b0020","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2147\/IJN.S402447","article-title":"Nose to brain delivery of astaxanthin\u2013loaded nanostructured lipid carriers in rat model of alzheimer\u2019s disease: Preparation, in vitro and in vivo evaluation","volume":"18","author":"Shehata","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2026.115161_b0025","article-title":"Formulation strategies for nose-to-brain drug delivery in Alzheimer\u2019s disease","volume":"6","author":"Vohra","year":"2023","journal-title":"Health Sci Rev."},{"key":"10.1016\/j.ejpb.2026.115161_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12951-023-01957-5","article-title":"Detection of \u03b2-amyloid aggregates\/plaques in 5xFAD mice by labelled native PLGA nanoparticles: implication in the diagnosis of Alzheimer\u2019s disease","volume":"21","author":"Govindarajan","year":"2023","journal-title":"J Nanobiotechnology."},{"key":"10.1016\/j.ejpb.2026.115161_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1474043","article-title":"Alzheimer\u2019s disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges","volume":"11","author":"Safiri","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.ejpb.2026.115161_b0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.30773\/pi.2020.0329","article-title":"The Behavioral effects of combination therapy of memantine and acetylcholinesterase inhibitors compared with acetylcholinesterase inhibitors alone in patients with moderate Alzheimer\u2019s dementia: A double-blind randomized placebo-controlled trial","volume":"18","author":"Youn","year":"2021","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.ejpb.2026.115161_b0045","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1038\/s44319-024-00294-4","article-title":"The controversy around anti-amyloid antibodies for treating Alzheimer\u2019s disease: The European Medical Agency\u2019s ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy","volume":"25","author":"Hunter","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejpb.2026.115161_b0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer\u2019s disease are reminiscent of the amyloid-\u03b2 story","volume":"18","author":"Imbimbo","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ejpb.2026.115161_b0055","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.2174\/0929867330666230112160522","article-title":"Side effects of Alzheimer\u2019s disease treatment","volume":"30","author":"Lazarevi\u0107-Pa\u0161ti","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejpb.2026.115161_b0060","article-title":"Utilization of nanotechnology to surmount the blood\u2013brain barrier in disorders of the central nervous system","volume":"31","author":"Luo","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.ejpb.2026.115161_b0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10787-024-01608-7","article-title":"Drugs repurposing in the experimental models of Alzheimer\u2019s disease","volume":"33","author":"Joodi","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejpb.2026.115161_b0070","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejpb.2026.115161_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.ejpb.2026.115161_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110002","article-title":"Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson\u2019s disease in rats: Targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p","volume":"362","author":"Motawi","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejpb.2026.115161_b0085","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115161_b0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejpb.2026.115161_b0095","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1007\/s10787-025-01755-5","article-title":"Empagliflozin and memantine combination ameliorates cognitive impairment in scopolamine + heavy metal mixture-induced Alzheimer\u2019s disease in rats: role of AMPK\/mTOR, BDNF, BACE-1, neuroinflammation, and oxidative stress","volume":"33","author":"Abdel-lah","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejpb.2026.115161_b0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/13872877251329474","article-title":"Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on A\u03b21\u201342 \u2212induced neurotoxicity and neuroinflammation in cellular models of Alzheimer\u2019s disease","volume":"105","author":"Alami","year":"2025","journal-title":"J Alzheimer\u2019s Dis."},{"key":"10.1016\/j.ejpb.2026.115161_b0105","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70704","article-title":"A phase 2A\/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD","volume":"21","author":"Erichsen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejpb.2026.115161_b0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/03639045.2022.2108829","article-title":"Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity","volume":"48","author":"Sinha","year":"2022","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0115","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/biomedicines11061752","article-title":"Nanomedicine in the Management of Alzheimer\u2019s Disease","volume":"11","author":"Mir Najib Ullah","year":"2023","journal-title":"State-of-the-Art. Biomedicines."},{"key":"10.1016\/j.ejpb.2026.115161_b0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","article-title":"Overcoming blood\u2013brain barrier transport: Advances in nanoparticle-based drug delivery strategies","volume":"37","author":"Ding","year":"2020","journal-title":"Mater. Today"},{"key":"10.1016\/j.ejpb.2026.115161_b0125","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.3390\/ijms25115842","article-title":"Nanoformulations in pharmaceutical and biomedical applications: Green perspectives","volume":"25","author":"Petrovic","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119033","article-title":"Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity","volume":"577","author":"Khan","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127938","article-title":"Surface-functionalized nanoparticles for targeted drug delivery across the blood\u2013brain barrier: Advances and challenges in neurodegenerative disease therapy","volume":"433","author":"Pramoda","year":"2025","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2026.115161_b0140","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2174\/1389200221666200719003304","article-title":"Nanostructured lipid carriers (NLCs): Nose-to-brain delivery and theranostic application","volume":"21","author":"Ahmad","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2026.115161_b0145","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to brain delivery of Rivastigmine by in situ gelling cationic nanostructured lipid carriers: Enhanced brain distribution and pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/2210303109666190926110927","article-title":"Nasal In-situ Gel: An approach to enhance therapeutic benefits of the drug","volume":"10","author":"Khatri","year":"2020","journal-title":"Drug Deliv. Lett."},{"key":"10.1016\/j.ejpb.2026.115161_b0155","article-title":"Nose to brain delivery of escitalopram-loaded nano-structured lipid carriers thermosensitive gel: Formulation, physiochemical, pharmacokinetic and pharmacodynamics evaluation","volume":"97","author":"Jawad","year":"2024","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0160","article-title":"Intranasal empagliflozin-loaded PLGA nanoparticles demonstrate neuroprotective effects against methotrexate-induced chemobrain in rats","volume":"112","author":"Mehanny","year":"2025","journal-title":"J. Drug. Deliv Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0165","article-title":"Development, optimization, and evaluation of Empagliflozin nanoemulsion for the management of neuroinflammation associated Alzheimer\u2019s disease","volume":"93","author":"Alhakamy","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105158","article-title":"Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice","volume":"150","author":"Khan","year":"2021","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejpb.2026.115161_b0175","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.fct.2009.11.003","article-title":"Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic","volume":"48","author":"Benford","year":"2010","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2026.115161_b0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Cheminformatics."},{"key":"10.1016\/j.ejpb.2026.115161_b0185","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1021\/ja0410237","article-title":"ChemDraw Ultra 9.0. CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www. cambridgesoft.com. see web site for pricing options","volume":"127","author":"Cousins","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2026.115161_b0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13346-016-0350-7","article-title":"Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contact dermatitis","volume":"7","author":"Shrotriya","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115161_b0195","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3390\/pharmaceutics15071985","article-title":"Development of atomoxetine-loaded NLC In situ gel for nose-to-brain delivery: Optimization, in vitro, and preclinical evaluation","volume":"15","author":"Mohanty","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115161_b0200","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/polym16213062","article-title":"Chitosan Nanoparticles embedded in In Situ Gel for Nasal delivery of Imipramine Hydrochloride: Short-Term Stage Development and Controlled Release Evaluation","volume":"16","author":"Adwan","year":"2024","journal-title":"Polymers"},{"key":"10.1016\/j.ejpb.2026.115161_b0205","article-title":"Intranasal atorvastatin-loaded vitamin E TPGS Lipoidal Nanocarriers for glioblastoma: QBD-enabled Formulation development and pharmacological investigations","volume":"107288","author":"Nikam","year":"2025","journal-title":"J Drug Deliv Sci Technol. Elsevier BV"},{"key":"10.1016\/j.ejpb.2026.115161_b0210","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/10717544.2014.900154","article-title":"QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance","volume":"22","author":"Beg","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115161_b0215","article-title":"Bioavailability enhancement of repaglinide from transdermally applied nanostructured lipid carrier gel: Optimization, in vitro and in vivo studies","volume":"57","author":"Pandey","year":"2020","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejpb.2017.01.008","article-title":"Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies","volume":"114","author":"Fathalla","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/IECP2020-08648","article-title":"Thermosensitive nasal in situ gels of lipid-based nanosystems to improve the treatment of Alzheimer\u2019s Disease","author":"Cunha","year":"2020","journal-title":"1st Int Electron Conf Pharm. MDPI"},{"key":"10.1016\/j.ejpb.2026.115161_b0230","article-title":"Novel nasal niosomes loaded with lacosamide and coated with chitosan: A possible pathway to target the brain to control partial-onset seizures","volume":"6","author":"Tulbah","year":"2023","journal-title":"Int J Pharm x."},{"key":"10.1016\/j.ejpb.2026.115161_b0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejps.2012.10.029","article-title":"Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa","volume":"48","author":"Pund","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118977","article-title":"Implementation of Quality by Design (QbD) approach in development of silver sulphadiazine loaded egg oil organogel: an improved dermatokinetic profile and therapeutic efficacy in burn wounds","volume":"576","author":"Thakur","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12249-019-1331-1","article-title":"Systematically optimized imiquimod-loaded novel hybrid vesicles by employing design of experiment (DoE) approach with improved biocompatibility, stability, and dermatokinetic profile","volume":"20","author":"Sharma","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115161_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.142861","article-title":"Nose-to-brain delivery of sorafenib-loaded lipid-based poloxamer-carrageenan nanoemulgel: Formulation and therapeutic investigation in glioblastoma-induced orthotopic rat model","volume":"309","author":"Khot","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2026.115161_b0255","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.xphs.2020.04.007","article-title":"Coated Lipidic nanoparticles as a new strategy for enhancing nose-to-brain delivery of a hydrophilic drug molecule","volume":"109","author":"Salem","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09925","article-title":"Nose to brain delivery of nanosuspensions with first line antiviral agents is alternative treatment option to Neuro-AIDS treatment","volume":"8","author":"Kakad","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejpb.2026.115161_b0265","doi-asserted-by":"crossref","first-page":"10436","DOI":"10.1039\/D1NR00901J","article-title":"Imaging of nanoparticle uptake and kinetics of intracellular trafficking in individual cells","volume":"13","author":"Vtyurina","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2026.115161_b0270","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuro.2018.11.012","article-title":"Ameliorative effect of alendronate against intracerebroventricular streptozotocin induced alteration in neurobehavioral, neuroinflammation and biochemical parameters with emphasis on A\u03b2 and BACE-1","volume":"70","author":"Zameer","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejpb.2026.115161_b0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40005-024-00696-5","article-title":"Neuroprotective role of Origanum majorana essential oil loaded in mixed surfactants based nano emulsion against lipopolysaccharide-induced Alzheimer in mice","volume":"55","author":"Salama","year":"2025","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2026.115161_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2023.103560","article-title":"Sterubin protects against chemically-induced Alzheimer\u2019s disease by reducing biomarkers of inflammation- IL-6\/ IL-\u03b2\/ TNF-\u03b1 and oxidative stress- SOD\/MDA in rats","volume":"30","author":"Kazmi","year":"2023","journal-title":"Saudi J Biol Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0285","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13318-020-00662-0","article-title":"Pharmacokinetic modelling of human recombinant protein, p75ECD-fc: A Novel therapeutic approach for treatment of Alzheimer\u2019s disease, in serum and tissue of sprague dawley rats","volume":"46","author":"Kelliny","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2026.115161_b0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0295","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/pharmaceutics13040531","article-title":"Development of a nanostructured lipid carrier (NLC) by a low-energy method, comparison of release kinetics and molecular dynamics simulation","volume":"13","author":"Ortiz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115161_b0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s43094-020-00023-3","article-title":"Application of Box\u2013Behnken design and desirability function in the development and optimization of self-nanoemulsifying drug delivery system for enhanced dissolution of ezetimibe","volume":"6","author":"Yadav","year":"2020","journal-title":"Future J Pharm Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0305","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1039\/D4PM00057A","article-title":"Insight into central nervous system targeted nanostructured lipid carriers via the nose to brain pathway","volume":"1","author":"Das","year":"2024","journal-title":"RSC Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0310","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.2147\/IJN.S274352","article-title":"Quality by Design Approach for Preparation of Zolmitriptan\/Chitosan Nanostructured Lipid Carrier Particles \u2013 Formulation and Pharmacodynamic Assessment","volume":"15","author":"Awadeen","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2026.115161_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111919","article-title":"Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design","volume":"141","author":"Agrawal","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2026.115161_b0320","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12247-019-09418-z","article-title":"Full Factorial Design, Optimization, In vitro and Ex vivo Studies of Ocular Timolol-Loaded Microsponges","volume":"15","author":"Abd-Elal","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.ejpb.2026.115161_b0325","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/10837450.2013.867445","article-title":"Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement","volume":"20","author":"Mandpe","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0330","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/pharmaceutics15082025","article-title":"Effects of adding Chitosan on drug entrapment efficiency and release duration for paclitaxel-loaded hydroxyapatite\u2014gelatin composite microspheres","volume":"15","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115161_b0335","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.3c08428","article-title":"Ezetimibe-Loaded nanostructured lipid carrier for oral delivery: Response surface methodology; in vitro characterization and assessing the antihyperlipidemic effect in rats","author":"Elkhayat","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2026.115161_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124391","article-title":"Fabrication of acetazolamide loaded leciplex for intraocular delivery: Optimization by 32 full factorial design, in vitro, ex vivo and in vivo pharmacodynamics","volume":"661","author":"Bagul","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0345","article-title":"Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design","volume":"683","author":"Peng Fang","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2026.115161_b0350","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpharm.2016.12.010","article-title":"Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s)","volume":"517","author":"Garg","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0355","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.11.014","article-title":"Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: Behavioral and biochemical evidence","volume":"747","author":"Sachdeva","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115161_b0360","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1028415X.2020.1764290","article-title":"Phytol loaded PLGA nanoparticles ameliorate scopolamine-induced cognitive dysfunction by attenuating cholinesterase activity, oxidative stress and apoptosis in Wistar rat","volume":"25","author":"Sathya","year":"2022","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.ejpb.2026.115161_b0365","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jddst.2017.07.006","article-title":"Formulation and development of Silybin loaded solid lipid nanoparticle enriched gel for irritant contact dermatitis","volume":"41","author":"Shrotriya","year":"2017","journal-title":"J Drug Deliv Sci Technol."},{"key":"10.1016\/j.ejpb.2026.115161_b0370","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/pharmaceutics13040581","article-title":"Sesame oil-based nanostructured lipid carriers of nicergoline, intranasal delivery system for brain targeting of synergistic cerebrovascular protection","volume":"13","author":"Abourehab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115161_b0375","first-page":"36","article-title":"Development and evaluation of a poloxamer- and chitosan-based in situ gel-forming injectable depot","author":"Nair","year":"2020","journal-title":"Asian J Pharm Clin Res. Innovare Academic Sciences Pvt Ltd"},{"key":"10.1016\/j.ejpb.2026.115161_b0380","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejpb.2010.02.011","article-title":"A poloxamer\/chitosan in situ forming gel with prolonged retention time for ocular delivery","volume":"75","author":"Gratieri","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106294","article-title":"Drug delivery to the brain: In situ gelling formulation enhances carbamazepine diffusion through nasal mucosa models with mucin","volume":"179","author":"Corazza","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0390","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12249-018-1213-y","article-title":"Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for CNS delivery: Optimization and Hematological toxicity studies","volume":"20","author":"Gadhave","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115161_b0395","article-title":"Unraveling the role of chitosan for nasal drug delivery systems: A review","volume":"5","author":"Kaur","year":"2023","journal-title":"Carbohydr. Polym. Technol. Appl."},{"key":"10.1016\/j.ejpb.2026.115161_b0400","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/2230-973X.147233","article-title":"Formulation and evaluation of clindamycin HCL in situ gel for vaginal application","volume":"5","author":"Patel","year":"2015","journal-title":"Int J Pharm Investig."},{"key":"10.1016\/j.ejpb.2026.115161_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106683","article-title":"Formulation optimization and evaluation of oromucosal in situ gel loaded with silver nanoparticles prepared by green biosynthesis","volume":"193","author":"Roha\u013eov\u00e1","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24217","article-title":"Preparation and characterization of a nanohydroxyapatite and sodium fluoride loaded chitosan-based in situ forming gel for enamel biomineralization","volume":"10","author":"Rafiee","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejpb.2026.115161_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121198","article-title":"Levosulpiride-loaded nanostructured lipid carriers for brain delivery with antipsychotic and antidepressant effects","volume":"311","author":"Maqsood","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2026.115161_b0420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.chemphyslip.2018.09.007","article-title":"Preparation and characterization of nanostructured lipid carriers as drug delivery system: Influence of liquid lipid types on loading and cytotoxicity","volume":"216","author":"Saedi","year":"2018","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ejpb.2026.115161_b0425","article-title":"Exploring the ovine anatomy: A comprehensive study of the sheep\u2019s head for basic training in functional endoscopic sinus surgery","author":"Stan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejpb.2026.115161_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123566","article-title":"A Nanoemulgel for Nose-to-Brain delivery of Quetiapine \u2013 QbD-Enabled formulation development & in-vitro characterization","volume":"648","author":"Gadhave","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115161_b0435","first-page":"2539","article-title":"Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study. Drug Deliv","volume":"14","author":"Ibrahim","year":"2024","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115161_b0440","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.biomaterials.2011.12.034","article-title":"The effect of chitosan on transcellular and paracellular mechanisms in the intestinal epithelial barrier","volume":"33","author":"Rosenthal","year":"2012","journal-title":"Biomaterials"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:38:53Z","timestamp":1790109533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":88,"alternative-id":["S0939641126001827"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115161","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115161"}}